GlassScriptPhysician profile
Paloma Camacho
NPI 1952837759
$2,050.45
in general payments reported to CMS, 2019-2025
19 companies · $1,021 in 2025
The $1,021 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $63.71 · 2022: $353 · 2023: $267 · 2024: $346 · 2025: $1,021.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,391 · Travel and Lodging: $242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,391.30 |
| Travel and Lodging | $242.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $625.17 | 2025 | Linq II, Micra, Crome Dr Mri Surescan |
| Sumitomo Pharma America, INC. | $186.13 | 2023 | Myfembree |
| Myovant Sciences INC. | $168.49 | 2021-2022 | |
| Edwards Lifesciences Corporation | $163.82 | 2025 | Sapien 3 Ultra Resilia |
| Novo Nordisk INC | $151.62 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $123.38 | 2022-2025 | |
| Pfizer INC. | $112.61 | 2021-2023 | |
| Hologic Sales and Service, LLC | $104.27 | 2023-2025 | Aptima, Thinprep 2000 Processor |
| Fresenius USA Marketing, INC. | $96.57 | 2024 | Velphoro |
| Kestra Medical Technology Services, INC. | $62.58 | 2025 | Assure Wcd |
| Merck Sharp & Dohme LLC | $41.53 | 2025 | Verquvo, Capvaxive |
| Daiichi Sankyo INC. | $40.89 | 2022 | |
| Astellas Pharma US INC | $33.36 | 2024 | Veozah |
| Organon LLC | $33.04 | 2022 | |
| Tandem Diabetes Care, INC. | $27.36 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $25.16 | 2025 | Zurzuvae |
| Therapeuticsmd, INC. | $23.05 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.00 | 2021 | |
| Amgen INC. | $15.42 | 2025 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paloma Camacho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.